From April this year to now, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. has been investigated and punished by the drug regulatory department seven times. China Net Finance noted that the company was repeatedly investigated and involved in the production and sale of substandard drugs, inferior drugs and so on.
On October 18, the Administrative Penalty Decision issued by the Anhui Provincial Drug Administration pointed out that on February 25, 2021, following the Anhui Provincial Drug Administration's "Letter on transferring unqualified drug inspection reports" (Drug Supervision Letter (2021) No. 64), the Shanxi Provincial Food and Drug Inspection Institute issued an unqualified report, report number: CY202006795, the name of the inspection product: Hot Sheep Herb (batch number: 191102), the production unit: Anhui Pharmaceutical Zhiyuan Chinese Medicine Tablet Co., Ltd., Inspection result: [content determination] 0.39% (the standard provisions shall not be less than 0.60%), does not meet the regulations.
On March 22, 2021, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. submitted a re-inspection to the China Food and Drug Inspection Institute, and on April 27, 2021, it received a re-inspection report from the China Inspection Institute (No. ZF202102575), and the inspection result: [Content Determination] 0.34% (the standard provisions shall not be less than 0.60%), which does not meet the regulations.
On March 12, 2021, law enforcement officers from the Anhui Provincial Drug Administration conducted an on-site inspection of the enterprise, and the enterprise admitted that the above-mentioned goat weed (batch number: 191102) was produced and sold by the company.
On October 18, the Anhui Provincial Drug Administration confiscated the unqualified products generated and sold by the company and confiscated 13,315 yuan of illegal gains, and imposed a fine of 39,812,500 yuan in accordance with Article 74 of the Drug Administration Law of the People's Republic of China (2015 Amendment).
China Net Finance noted that since April this year, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. has been investigated and punished by the drug regulatory department 7 times.
On April 1, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. was fined for its involvement in the production and sale of inferior drugs Cang shu case and the production and sale of inferior drugs Qianhu case;
On June 1, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. was fined 60,000 yuan by the regulatory authorities for its involvement in the lending of the Drug Production License.
According to the data, Anhui Yaozhiyuan Chinese Medicine Tablet Co., Ltd. was registered and established in Bozhou in 2015, which can produce and process nearly 600 kinds of Chinese medicine tablets, and the current legal representative is Li Yunti.
(Editor-in-charge: Zhao Rong)